Spectrometry News and Research

RSS

KineMed's fibrosis research program featured in Nature Medicine

KineMed Inc.'s fibrosis research program, which aims to advance the discovery and development of drugs to treat this major disease, is featured in the January edition of Nature Medicine.

24 Jan 2011

Waters signs land-purchase agreement with Royal Bank of Scotland for new MS Headquarters in UK

Waters Corporation today announced it signed a land-purchase agreement with The Royal Bank of Scotland for a new Mass Spectrometry Headquarters in Wilmslow, Cheshire, near Manchester, U.K.

20 Jan 2011

Metabolic profiling of tissue samples may transform the way surgeons make decisions

Metabolic profiling of tissue samples could transform the way surgeons make decisions in the operating theatre, say researchers at a new laboratory being launched today. Scientists at Imperial College London, in partnership with clinicians at Imperial College Healthcare NHS Trust, have installed a high resolution solid state nuclear magnetic resonance (NMR) spectrometer in St Mary's Hospital.

13 Jan 2011

UnitedHealthcare selects Millennium as participating provider of pain management services

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain, announced it will provide pain management and therapeutic drug monitoring services to physicians participating in UnitedHealthcare's national care provider network.

12 Jan 2011

Vermillion receives USPTO patent for PAD biomarker

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued patent number 7,867,719 entitled "Beta-2 microglobulin as a biomarker for peripheral artery disease" to the Company.

12 Jan 2011

New technique to analyze and quantify changes in protein

A scientist from the Florida campus of The Scripps Research Institute has devised a new method of analyzing and quantifying changes in proteins that result from a common chemical process. The new findings could provide new insights into the effects of a highly destructive form of stress on proteins in various disease models, particularly cancer.

6 Jan 2011

KINAXO, AstraZeneca enter oncology research collaboration

KINAXO Biotechnologies GmbH announced today that it has entered into a collaboration with AstraZeneca. Under the terms of the agreement, KINAXO will apply its technology platform to support one of AstraZeneca's oncology programs. KINAXO will employ high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale.

5 Jan 2011

Fabric softener sheets repel fungus gnat adults under laboratory conditions

For years, gardeners have claimed that putting Bounce- fabric softener sheets in their pockets is an effective way to repel pests like mosquitoes and gnats.

16 Dec 2010

New study contradicts presence of oxysterols in multiple sclerosis patients

New research findings appearing in the January Journal of Lipid Research indicate that compounds called oxysterols are not present in any significant amount in multiple sclerosis patients, contradicting a previous study that suggested that some of these cholesterol metabolites were associated with MS and could be used as diagnostic tools in the clinic.

16 Dec 2010

Echo acoustic liquid handler improves discovery of potential therapeutics

When the revolutionary Echo® acoustic liquid handler is used in the process of discovering potential therapeutics, important drug candidates are identified that are missed using traditional liquid handlers. In a recently issued patent, the global pharmaceutical company AstraZeneca describes the discovery of a novel set of potential cancer therapeutics that was found only when the Echo system was used. Other major pharmaceutical companies have also reported that the Echo liquid handler was a critical platform in discovering drug candidates.

15 Dec 2010

APHP selects Bruker´s Biotyper as exclusive MALDI-TOF mass spectrometry for microbial identification

At the 30th Reunion Interdisciplinaire de Chimothérapie Anti-Infectieuse (RICAI), Bruker announces that the Assistance Publique Hôpitaux de Paris (APHP) has selected Bruker´s IVD MALDI Biotyper as their exclusive MALDI-TOF mass spectrometry-based microbial identification tool.

2 Dec 2010

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.

30 Nov 2010

New irreversible covalent approach to inhibit viral protease

28 Nov 2010

Agilent releases GeneSpring GX 11.5 multi-omics bioinformatics system

Agilent Technologies Inc. today introduced GeneSpring GX 11.5, an expansion of its popular bioinformatics software into visualizing and analyzing multiple types of biological data. GeneSpring GX 11.5 now interprets exon microarray, proteomics and metabolomics experiments together for the first time, using a familiar interface.

23 Nov 2010

Agilent's GeneSpring Bioinformatics Solution integrated with GeneGo's MetaCore

GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, and Agilent Technologies, Inc., the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications, announced today that they have integrated Agilent's GeneSpring Bioinformatics Solution with MetaCore.

22 Nov 2010

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.

20 Nov 2010

New technique to identify cancer biomarkers

The University of Liège has presented TARGETOME, the most recent of its spin-offs, which is also the first to spring from its applied geno-proteomics centre, GIGA.

18 Nov 2010

New OncoMap technique can detect point mutation in ovarian cancer

Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.

17 Nov 2010

NovAliX enters agreement to acquire Graffinity

NovAliX SAS today announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH of Heidelberg, Germany, a leading fragment based drug discovery services company.

16 Nov 2010

ICON, Proteome enter alliance to provide expanded biomarker solutions

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Proteome Sciences a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.

15 Nov 2010